Johann de Bono: h-index, Total Citations, and Citation Map
Johann de Bono's h-index is 166 (832 i10-index, 145,480+ total citations across 4+ publications) according to Google Scholar as of May 2026. Johann de Bono is affiliated with Institute of Cancer Research.
Johann de Bono is a researcher affiliated with Institute of Cancer Research, specializing in Cancer. Their work has been cited 145,480 times. This profile visualizes their global influence, highlighting strong citation networks in United States.
Johann de Bono's Citation Metrics
Bibliometric impact based on 4 indexed publications.
- H-Index
- 166
- i10-Index
- 832
- Total Citations
- 145,480
- Citing Countries
- 27
As of May 2026.
Johann de Bono has an h-index of 166 and 145,480 total citations across 4 publications, with research cited by institutions in 27 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Johann de Bono's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
We've mapped 5,000 of 145,480 citations for Johann de Bono
We've shown the most-cited 5,000. Unlock the full crawl (145,448 more citations) to see every institution citing this scholar.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Top Cited Works
Tip: clickto hide a row from the map
Increased survival with enzalutamide in prostate cancer after chemotherapy
20125,821
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
The researcher advanced prostate cancer treatment by demonstrating enzalutamide's survival benefits post-chemotherapy and integrating clinical genomics to refine advanced disease management strategies.
The researcher published a seminal NEJM paper demonstrating the efficacy of PARP inhibition in tumors from BRCA mutation carriers, establishing a foundational clinical strategy for targeted cancer therapy.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
